Lee J, Li C, Huang H, Zhu M, Mariño-Enríquez A, Lee C, et al. ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma. J Pathol. 2017;241:316-323 pubmed publisher

Onaindia A, Montes-Moreno S, Rodriguez-Pinilla S, Batlle A, Gonzalez de Villambrosia S, Rodriguez A, et al. Primary cutaneous anaplastic large cell lymphomas with 6p25.3 rearrangement exhibit particular histological features. Histopathology. 2015;66:846-55 pubmed publisher

Vishwamitra D, Curry C, Alkan S, Song Y, Gallick G, Kaseb A, et al. The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK⁺ T-cell lymphoma. Mol Cancer. 2015;14:53 pubmed publisher

George S, Vishwamitra D, Manshouri R, Shi P, Amin H. The ALK inhibitor ASP3026 eradicates NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model. Oncotarget. 2014;5:5750-63 pubmed

Suzuki O, Abe M. Galectin-1-mediated cell adhesion, invasion and cell death in human anaplastic large cell lymphoma: regulatory roles of cell surface glycans. Int J Oncol. 2014;44:1433-42 pubmed publisher

Yang Y, Li Y, Liu Y, Yang M, Liu K. CD30(+) extranodal natural killer/T-cell lymphoma mimicking phlegmonous myositis: A case report. Oncol Lett. 2014;7:1419-1421 pubmed